BS01 in Patients With Retinitis Pigmentosa

Last updated: January 21, 2026
Sponsor: Bionic Sight LLC
Overall Status: Active - Recruiting

Phase

1/2

Condition

Eye Disorders/infections

Posterior Uveitis

Retinitis Pigmentosa

Treatment

BS01

Clinical Study ID

NCT04278131
BS01-RP-001
  • Ages > 18
  • All Genders

Study Summary

A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed diagnosis of retinitis pigmentosa

  • At least one eye with vision no better than 20/160 visual acuity on the EDTRS scaleor, for patients with peripheral vision loss, a visual field no greater than 30°.

Exclusion

Exclusion Criteria:

  • Prior receipt of any AAV gene therapy product

  • Large amplitude nystagmus

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: BS01
Phase: 1/2
Study Start date:
February 06, 2020
Estimated Completion Date:
December 30, 2029

Connect with a study center

  • New Jersey Retina

    Teaneck, New Jersey 07666
    United States

    Site Not Available

  • New Jersey Retina

    Teaneck 5105262, New Jersey 5101760 07666
    United States

    Active - Recruiting

  • OCLI

    New York, New York 11572
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.